Drug interactions between antiretrovirals and hormonal contraceptives.
about
Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practicesPregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort studyIntravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIVHIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restrictionEffect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy.Clinical versus laboratory screening for sexually transmitted infections prior to insertion of intrauterine contraception among women living with HIV/AIDS: a randomized controlled trialDolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.Sexually transmitted infections and use of contraceptives in women living with HIV in Denmark - the SHADE cohortThe effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception.Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data.Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.Drug interactions between hormonal contraceptives and antiretrovirals.Contraceptive options for HIV-positive women: making evidence-based, patient-centred decisions.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine ProductsEfavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.Current and future contraceptive options for women living with HIV.Repeated administration of high-dose depot medroxyprogesterone acetate does not alter SHIVSF162p3 viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings.Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive.Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.Role of CYP3A in Oral Contraceptives Clearance.Thai national guidelines for the prevention of mother-to-child transmission of human immunodeficiency virus 2017.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q28067469-DD44BF6B-C6F3-4D3F-BCFC-4A76274985F5Q28081707-F6E5F285-4481-40D0-B6A1-5FAD1BD7D3FFQ30447923-0C6B7279-0975-4B53-B364-B3A22791B54AQ34538556-2367C2E4-4F69-4932-9E3A-2C87FB60413DQ34687799-F4F7B8AB-8AEF-41B3-B56E-2BA51793CA65Q34923455-5F638C2E-20F9-4CEE-B1CA-ACF8C8CB67D0Q35569646-B1004214-EEB7-441F-B2F1-A1A79A396433Q35755652-DD342D7F-296A-4E2F-A40B-6F73AC71F6A5Q35756542-04C51B18-814B-430C-B91B-C2BFF35FFE2FQ35924550-F679692A-2439-4C86-9B7D-C5589DC7BF0FQ36306216-1401E0FE-C6A2-4A50-9798-F1BA51C8174AQ36343568-EE4E91EC-F175-413E-94F5-9D4741CF61D1Q36816616-8598FA1E-C7A6-416A-AACF-F2EF36ECE887Q37624319-553E0BE0-EA29-48E0-9A46-FE26AD47CBBAQ37735345-D81F62B5-F6C9-441B-B9A9-B1A5F7115282Q38358383-18B60850-3CF6-4835-8743-AC3955A6A049Q38513275-B00C13FE-8975-414D-B450-A861355697A4Q38686382-C238F01D-09AA-4E89-BA48-8CADCA8AF994Q38719799-BEDD9023-1AA9-4CD6-A3DA-EF71745B74DCQ38771869-3C9DAEC8-0C3E-4F37-B316-D9DBEB49AD8DQ40048203-27EFAB37-8CAE-405F-A87A-82A51261D6D6Q40106510-0BF6CDAE-617B-46F0-B59C-0E7A13EFFC6BQ46458190-AB8DFC17-3728-4DD0-B972-740A9458097EQ48524975-172D080B-DCC2-4720-9634-3267746E2CDFQ49544121-B58610DF-0186-4AFE-91B4-6D84D7285BD1Q55154875-B51CBE55-E127-4044-A24F-16B686D6849AQ58073610-FF39CEBB-D414-4C71-9F8E-191F38BD739F
P2860
Drug interactions between antiretrovirals and hormonal contraceptives.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug interactions between antiretrovirals and hormonal contraceptives.
@en
type
label
Drug interactions between antiretrovirals and hormonal contraceptives.
@en
prefLabel
Drug interactions between antiretrovirals and hormonal contraceptives.
@en
P2860
P1476
Drug interactions between antiretrovirals and hormonal contraceptives
@en
P2093
Cara Hills-Nieminen
P2860
P304
P356
10.1517/17425255.2013.772579
P407
P50
P577
2013-02-21T00:00:00Z